Key result
LCZ696 significantly reduced the risk of renal function deterioration compared to ACEI/ARB in patients with heart failure (OR 0.77, p=0.02).
Why the study?
Patients with HF are prone to renal insufficiency, but whether LCZ696 is better than ACEI/ARB in renal protection had not been investigated.
Does LCZ696 reduce the risk of renal function deterioration in patients with heart failure compared to ACEI/ARB?
Meta-Analysis (n=14,959)
Double-blind
Randomized
Yes
Does LCZ696 reduce the risk of renal function deterioration in patients with heart failure compared to ACEI/ARB?
Odds Ratio: 0.77 (95% CI 0.61–0.97)
p-value: p=0.02
In patients with heart failure, LCZ696 (sacubitril/valsartan) provides superior renal protection by significantly reducing the risk of worsening renal function compared to ACEI/ARB.
May favor LCZ696 over ACEI/ARB for renal preservation in HF; extends individual RCT data via pooled analysis.
Patients with heart failure (HF) are prone to combine with renal insufficiency. Recently, LCZ696 has been used in the treatment of HF, but whether LCZ696 is better than angiotensin converting enzyme inhibitors/angiotensin receptor antagonists (ACEI/ARB) in renal protection for HF patients has not been investigated. Therefore, we conducted a meta-analysis focusing on LCZ696 and its role in preservation of renal function in HF patients. Embase, PubMed, the Cochrane Library and ClinicalTrials.gov databases were electronically searched for available randomized controlled trials (RCTs). HF patients taking LCZ696 or ACEI/ARB were assessed for renal adverse events. The last search date was Sep 20, 2019. A total of 14959 patients from 6 trials were included in this meta-analysis. As compared to ACEI/ARB, LCZ696 significantly reduced the risk of renal function deterioration (odds ratio 0.77, 95% confidence interval 0.61-0.97, P = 0.02). In summary, LCZ696 may have superior renal protection in HF patients compared with ACEI/ARB.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted a meta-analysis in Heart failure (n=14,959). LCZ696 vs. ACEI/ARB was evaluated on Renal function deterioration (OR 0.77, 95% CI 0.61-0.97, p=0.02). LCZ696 significantly reduced the risk of renal function deterioration compared to ACEI/ARB in patients with heart failure (OR 0.77, p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: